Ftse Mib
33.746,66
-1,60%
DAX
17.932,17
-1,10%
S&P 500
5.035,69
-1,57%
NASDAQ Composite
15.657,82
-2,04%
Bitcoin
57.179,18
-5,68%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Lyra Therapeutics Inc (LYRA) Lyra Therapeutics Inc (LYRA) Notizie

Lyra Therapeutics Inc

LYRA
5,16
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 10:16:54
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
30/4/202422:04GLOBELyra Therapeutics Reports First Quarter 2024 Financial..
26/4/202422:51GLOBELyra Therapeutics Announces Inducement Grants Under Nasdaq..
21/3/202421:01GLOBELyra Therapeutics Reports Fourth Quarter and Full Year 2023..
01/3/202422:01GLOBELyra Therapeutics Announces Inducement Grant Under Nasdaq..
15/2/202415:18EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
15/2/202402:35EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
15/2/202400:18EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202422:51EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202422:18EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202422:34EDGAR2Form SC 13G - Statement of acquisition of beneficial..
01/2/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202412:13EDGAR2Form 8-K - Current report
28/12/202312:40EDGAR2Form 8-K - Current report
18/12/202322:16EDGAR2Form 8-K - Current report
16/11/202323:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
13/11/202323:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/11/202322:23EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202322:09EDGAR2Form 8-K - Current report
07/11/202322:01GLOBELyra Therapeutics Reports Third Quarter 2023 Financial..
07/11/202313:00GLOBELyra Therapeutics to Participate in Upcoming Investor..
16/10/202313:00GLOBELyra Therapeutics Announces Appointment of Ronan O’Brien as..
12/9/202322:01EDGAR2Form 8-K - Current report
12/9/202313:00GLOBELyra Therapeutics Announces Positive Topline Results from..
06/9/202314:00GLOBELyra Therapeutics to Participate in Upcoming Investor..
01/9/202322:03EDGAR2Form 8-K - Current report
01/9/202322:01EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/8/202313:00GLOBELyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I..
25/8/202322:15EDGAR2Form SC 13G - Statement of acquisition of beneficial..
08/8/202322:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202322:03EDGAR2Form 8-K - Current report
08/8/202322:01GLOBELyra Therapeutics Reports Second Quarter 2023 Financial..
14/7/202322:06EDGAR2Form 8-K - Current report
13/7/202313:30GLOBELyra Therapeutics to Present at William Blair Virtual..
13/7/202300:36EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
07/7/202322:44EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
06/7/202303:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/7/202303:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/7/202303:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/6/202322:06EDGAR2Form S-3 - Registration statement under Securities Act of..
02/6/202322:01GLOBELyra Therapeutics Announces Inducement Grant Under Nasdaq..
02/6/202313:30GLOBELyra Therapeutics to Present at Jefferies Healthcare..
01/6/202313:29GLOBELyra Therapeutics Announces Closing of $50.0 Million Private..
26/5/202313:57GLOBELyra Therapeutics Announces $50.0 Million Private Placement
12/5/202313:00GLOBELyra Therapeutics Reports First Quarter 2023 Financial..
09/5/202322:01GLOBELyra Therapeutics to Present at Bank of America Securities..
Apertura: Min: Max:
Chiusura: 5,16

La tua Cronologia

NASDAQ
LYRA
Lyra Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network